Table 2.
Subgroup analysis of the adverse events between pregabalin and placebo groups
| Events | Incidence (number/total) | Heterogeneity | Effect model | Meta-analysis | |||
|---|---|---|---|---|---|---|---|
| Pregabalin | Placebo | I2 (%) | P | Relative risk (95% CI) | P | ||
| Somnolence | 75/202 | 29/194 | 78 | 0.01 | Random | 2.23 [0.97, 5.14] | < 0.05 |
| Dizziness | 44/202 | 18/194 | 32 | 0.23 | Fixed | 2.36 [1.42, 3.92] | < 0.05 |
| Dry mouth | 20/182 | 5/174 | 0 | 0.54 | Fixed | 3.82 [1.47, 9.96] | < 0.05 |
| Edema | 20/182 | 5/174 | 0 | 0.65 | Fixed | 3.83 [1.49, 9.85] | < 0.05 |
| Peripheral edema | 17/132 | 4/127 | 0 | 0.98 | Fixed | 4.11 [1.42, 11.85] | < 0.05 |